Overall survival · people with advanced gastric cancer
S‐1 showed no clear difference in overall Survival compared with 5‐FU‐containing regimens (high certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
It is very uncertain whether S‐1 changes tumour response compared with 5‐FU‐containing regimens (very low certainty).
1 finding from 1 review
Progression‐free survival · people with advanced gastric cancer
S‐1 showed no clear difference in progression‐free survival compared with 5‐FU‐containing regimens (low certainty).
1 finding from 1 review
Time‐to treatment failure · people with advanced gastric cancer
S‐1 showed no clear difference in time‐to treatment failure compared with 5‐FU‐containing regimens (low certainty).
1 finding from 1 review
Treatment‐related deaths · people with advanced gastric cancer
S‐1 showed no clear difference in treatment‐related deaths compared with 5‐FU‐containing regimens (moderate certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
S‐1 showed no clear difference in treatment discontinuation due to toxicity compared with 5‐FU‐containing regimens (high certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes all‐cause mortality at 1 year compared with S‐1 (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes serious adverse events compared with S‐1 (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes overall response rate compared with S‐1 (very low certainty).
1 finding from 1 review
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes grade 1 ‐ 4 anaemia compared with S‐1 (very low certainty).
1 finding from 1 review
All‐cause mortality: 1‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 1‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review
All‐cause mortality: 2‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 2‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review
Serious adverse events · people with resectable cholangiocarcinoma
1 finding from 1 review
Quality of life (2 weeks‐12 months) · people with inflammatory bowel disease
1 finding from 1 review
Recovery from probable PTSD in children (< 1 month post intervention) Defined by number of participants whose CRIES‐13 score was above cutoff for diagnosis of PTSD at baseline ‐ number of participants whose CRIES‐13 score was above cutoff for the ... · children/adolescents with post‐traumatic stress and related depressive/anxiety symptoms
It is very uncertain whether community professional‐led interventions changes recovery from probable PTSD in children (< 1 month post… compared with no care (very low certainty).
1 finding from 1 review
Proportion of participants returning to work in the medium term (6 months ‐ 1 year) · patients with coronary heart disease
Physical conditioning interventions showed no clear difference in proportion of participants returning to work in the medium term (6… compared with usual care (low certainty).
1 finding from 1 review
Severity of PTSD symptoms · adult survivors of the ICU, excluding those already in an existing follow‐up or rehabilitation programme
1 finding from 1 review
Treatment efficacy CAPS, SCID‐IV, PTSS‐10Q‐I · adult participants (18 years and older) who have been exposed to any traumatic events, but who did not meet the diagnostic criteria for…
Hydrocortisone probably leads to lower treatment efficacy CAPS, SCID‐IV, PTSS‐10Q‐I compared with placebo (moderate certainty).
1 finding from 1 review